Hint mode is switched on Switch off
For swift navigation between sections

Biontech Se
LEI 894500UZJ5LG1F8J1U58

PDF download

Choose all Reset all
Download Cancel
Organization name
Biontech Se
Country name
Germany
Country of registration
Germany
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

11/03/2026 Bank of America Reaffirms 'Buy' Rating for BioNTech Amid Strategic Shifts
16/01/2026 BioNTech (NASDAQ:BNTX) Shifts Focus to Oncology, Receives Buy Rating from Goldman Sachs
04/11/2025 BioNTech SE (NASDAQ: BNTX) Earnings Report Highlights
04/08/2025 BioNTech SE (NASDAQ:BNTX) Shows Promising Market Performance and Strategic Collaborations
All organization news

Documentation

IFRS/US GAAP reports

2025
IV q eng
2024
IV q eng
2023
IV q eng
2022
IV q eng
2021
IV q eng
2020
IV q eng
2019
IV q eng
Show all Hide
Authorization required
You need to request access

Affiliates

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    894500UZJ5LG1F8J1U58
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001776985
Registration is required to get access.